Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Zurn Elkay Water Solutions Corporation heads into its October 27 earnings report with the Street mildly cautious and options traders positioned as bullishly as they have been all year.
The most notable move this week came from RBC Capital, which trimmed its price target on ZWS to $54 from $58 on October 14, while keeping a Sector Perform rating. That cut runs against the grain of what most analysts did after last quarter's results. Following the Q2 print in late July, Stifel lifted its target to $62, Barclays went to $61, and Oppenheimer raised to $60 in September. The consensus target now sits around $57.56, roughly 22% above the current price of $47.19. Even RBC's lower target implies meaningful upside from here. The divergence between the bulls, who point to strong organic growth and institutional construction demand, and the more cautious framing of RBC, who hold a neutral-equivalent rating despite those same results, is the tension worth watching as the print approaches.
On valuation, ZWS trades at 23.7 times earnings and 14.9 times EV/EBITDA. Neither multiple is extreme for a business with this quality of execution. The bull case rests on 11% organic sales growth last quarter, 160 basis points of margin expansion, and a 0.5x net leverage ratio that leaves room for buybacks or bolt-on M&A. The bear case centres on execution risk if nonresidential construction activity slows, copper and brass cost pressure, and the risk that Elkay synergies disappoint. The EPS surprise factor score ranks in the 85th percentile, meaning ZWS has a strong track record of beating estimates, which gives the bulls a quantitative leg to stand on.
Options traders are positioned near the most call-heavy extreme of the past year. The put/call ratio has collapsed to 0.044, well below its 20-day average of 0.128. That reading sits more than 1.4 standard deviations below the mean, with the 52-week high at 0.97 as a reference point for how defensive positioning can get. The directional shift is sharp: through most of September the PCR ran between 0.15 and 0.21, then dropped abruptly in early October. Call demand has dominated entirely in the run-up to earnings. Short interest is not part of this story. At 2.8% of free float, with borrow costs at just 0.35% and availability at a very comfortable 3,153%, there is no meaningful short squeeze dynamic at play. The borrow market has actually loosened from a peak utilization of roughly 4% in mid-September to just over 3% now, which fits with the broader picture: this is not a stock under short-seller pressure.
The ownership register shows BlackRock holding 14.8% as the largest institutional owner, with State Street, Janus Henderson, and Invesco all adding shares in the most recent reported quarter. The most recent insider transaction of note was Chief Administrative Officer Mark Peterson selling 25,000 shares at $53.02 on August 4, a $1.3 million open-market sale with no 10b5-1 plan attached. Against that, the 90-day net insider position is negative at roughly $1.2 million sold. No 13D activists are on the register. The 13G holders are all passive index managers.
Wikipedia attention for ZWS spiked to a z-score of 6.2 in late September against its own trailing 90-day history, a notable spike in retail interest that has since faded. It bears no predictive weight on the earnings outcome, but it signals a brief moment of broader visibility for what is normally a quiet industrial name. With Q3 results due October 27 and the Street broadly constructive but RBC stepping back, the question heading into the print is whether the organic growth rate holds at or near the first-half pace, or whether education and healthcare budget pressures begin to show in the order book.
See the live data behind this article on ORTEX.
Open ZWS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
